Skip to content
OpenCapital
Get started

Larimar Therapeutics LRMR Q4 2024 Annual earnings

Reported March 24, 2025 · Before market open

Revenue$241.0KDiluted EPS-$0.45Miss by $0.16
EPS estimate-$0.29

Next report

Aug 13, 2026 (in a month)
EPS estimate-$0.39

Versus estimates

Revenue

Q4 2024$241.0K

Diluted EPS

Q1 2026-$0.31Beat by $0.22Q4 2025-$0.73Miss by $0.29Q3 2025-$0.61Miss by $0.22Q2 2025-$0.41Beat by $0.06Q1 2025-$0.46Miss by $0.04
Q4 2024-$0.45Miss by $0.16

Ask the moment Larimar Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Larimar Therapeutics report Q4 2024 earnings?
Larimar Therapeutics (LRMR) reported Q4 2024 earnings on March 24, 2025 before market open.
What were Larimar Therapeutics's Q4 2024 revenue and EPS?
Larimar Therapeutics reported revenue of $241.0K and diluted EPS of $-0.45 for Q4 2024.
Did Larimar Therapeutics beat estimates in Q4 2024?
EPS missed the consensus estimate of $-0.29 by $0.16.
Where can I find Larimar Therapeutics's Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-043925) directly on SEC EDGAR. The filing index links above go to sec.gov.